AMGN stock news

The biggest risk to Amgen stock comes from health reform that might limit the number of drugs insurers pay for, creating price competition. Read more
Tuesday's top analyst upgrades, downgrades and initiations included Amgen, Beyond Meat, Cisco, Home Depot, Microsoft, RingCentral, Shake Shack, Tilray, Uber, Under Armour and U.S. Steel. Read more
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 4) Agile Therapeutics Inc (NASDAQ: AGRX )(follow-on rally following positive Adcom verdict for Twirla) Amgen, Inc. (NASDAQ: AMGN ) Beigene Ltd (NASDAQ: BGNE ) Bioanalytical Systems, Inc. (NASDAQ: BASI ) Bio-Rad Laboratories, Inc. (NYSE: BIO ) Cabaletta Bio Inc (NASDAQ: CABA ) Deciphera Pharmaceuticals Inc (NASDAQ: DCPH ) Frequency Therapeutics Inc (NASDAQ: FREQ ) Horizon Therapeutics PLC (NASDAQ: HZNP ) Karyopharm Therapeutics Inc (NASDAQ: KPTI )(reacted to its third-quarter results) Oyster Point Pharma Inc (NASDAQ: OYST ) (IPOed Oct. 31) Phathom Pharmaceuticals Inc (NASDAQ: PHAT ) Recro Pharma Inc (NASDAQ: REPH ) ZEALAND PHARMA/S ADR (NASDAQ: ZEAL ) Down In The Dumps (Biotech stocks hitting 52-week lows on Nov. 4) Cleveland BioLabs, Inc. (NASDAQ: CBLI ) Helius Medical Technologies Inc (NASDAQ: HSDT ) Mersana Therapeutics Inc (NASDAQ: MRSN ) Midatech Pharma PLC-ADR (NASDAQ: MTP ) Rockwell Medical Inc (NASDAQ: RMTI ) Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH ) Stocks In Focus Seattle Genetics Claims Rights To Disputed Antibody-Drug Conjugate Intellectual Property Following the filing of a declaratory judgment action by DAIICHI SANKYO/S ADR (OTC: DSNKY ), Seattle Genetics, Inc. (NASDAQ: SGEN ) said the antibody-drug conjugate tech used in Daiichi Sankyo's metastatic cancer drug candidate DS-820 , among others, rightfully belongs to it. "The linker and other ADC technology used in these drug candidates are improvements to Seattle Genetics' pioneering ADC technology, the ownership of which are automatically assigned to Seattle Genetics under the terms of the agreement," the company said. Read more
REDWOOD CITY, Calif., Nov. 4, 2019 /PRNewswire/ -- Revolution Medicines, Inc., a clinical-stage oncology company focused on developing targeted therapies to inhibit elusive frontier targets within notorious cancer pathways, today announced an agreement with Amgen to evaluate the… Read more
Biotechnology company Amgen (NasdaqGS: AMGN) is throwing $2.7 billion into BeiGene (NasdaqGS: BGNE), sending the Chinese biotech's shares surging and bolstering sector-related ETFs. Read more
Here's a roundup of top developments in the … Full story available on Benzinga.com Read more
Amgen Inc said on Thursday it will take a 20.5% stake in BeiGene Ltd in a deal to expand the California-based biotechnology company's presence in China, the world's second largest pharmaceutical… | October 31, 2019 Read more
Amgen Inc said on Thursday it will acquire a 20.5% stake in BeiGene Ltd <6160.HK> in a deal that will enable the California-based biotechnology company to expand its presence in China, the world's second largest pharmaceutical market. Read more
Under the all-cash deal, Amgen will pay BeiGene shareholders $174.85 per share, a 25% premium to BeiGene's closing price on the Nasdaq on Wednesday. Read more

Biotech stocks win October, rallying 8%

03:18pm, Thursday, 31'st Oct 2019
The biotechnology sector is up over 8% in October, lead by large-cap companies Biogen, Amgen and Celgene. Read more
Der Umsatz dürfte 2019 nun bei 22,8 bis 23,0 Milliarden US-Dollar liegen, teilte das Unternehmen am Dienstag nach US-Börsenschluss in Thousand Oaks mit. Zuletzt hatte Amgen mit 22,4 bis 22,9 Milliarden Dollar gerechnet. Analysten erwarten bisher 22,8 Milliarden Dollar. Read more
Der Umsatz dürfte 2019 nun bei 22,8 bis 23,0 Milliarden US-Dollar liegen, teilte das Unternehmen am Dienstag nach US-Börsenschluss in Thousand Oaks mit. Zuletzt hatte Amgen mit 22,4 bis 22,9 Milliarden Dollar gerechnet. Analysten erwarten bisher 22,8 Milliarden Dollar. Read more
Markets are watching what Fed Chair Powell will signal for future rate cuts during this afternoon's FOMC rate decision….GE Read more
Q3 '19 EARNINGS CALL OCTOBER 29, 2019 SAFE HARBOR STATEMENT This… | October 30, 2019 Read more
Starting next year, Amgen Inc. will list Repatha for $5,850 a year for all insurers. It rolled out at that price last year, but still supplied the treatment at the original price of more than… | October 29, 2019 Read more

Proudly made at

ROCKIT